These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34716683)

  • 1. Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.
    Qiang M; Ma P; Li Y; Liu H; Harding A; Min C; Wang F; Liu L; Yuan M; Ji Q; Tao P; Shi X; Li Z; Li T; Wang X; Zhang Y; Wu NC; Lee CD; Zhu X; Gilbert-Jaramillo J; Zhang C; Saxena A; Huang X; Wang H; James W; Dwek RA; Wilson IA; Yang G; Lerner RA
    Adv Sci (Weinh); 2022 Jan; 9(1):e2102181. PubMed ID: 34716683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
    Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
    MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
    Zhao S; Zhang H; Yang X; Zhang H; Chen Y; Zhan Y; Zhang X; Jiang R; Liu M; Liu L; Chen L; Tang W; Peng C; Gao X; Zhang Z; Shi Z; Gong R
    Nat Commun; 2021 Aug; 12(1):4887. PubMed ID: 34373446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
    Bertoglio F; Meier D; Langreder N; Steinke S; Rand U; Simonelli L; Heine PA; Ballmann R; Schneider KT; Roth KDR; Ruschig M; Riese P; Eschke K; Kim Y; Schäckermann D; Pedotti M; Kuhn P; Zock-Emmenthal S; Wöhrle J; Kilb N; Herz T; Becker M; Grasshoff M; Wenzel EV; Russo G; Kröger A; Brunotte L; Ludwig S; Fühner V; Krämer SD; Dübel S; Varani L; Roth G; Čičin-Šain L; Schubert M; Hust M
    Nat Commun; 2021 Mar; 12(1):1577. PubMed ID: 33707427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
    Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
    Nat Chem Biol; 2021 Jan; 17(1):113-121. PubMed ID: 33082574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
    Noy-Porat T; Makdasi E; Alcalay R; Mechaly A; Levy Y; Bercovich-Kinori A; Zauberman A; Tamir H; Yahalom-Ronen Y; Israeli M; Epstein E; Achdout H; Melamed S; Chitlaru T; Weiss S; Peretz E; Rosen O; Paran N; Yitzhaki S; Shapira SC; Israely T; Mazor O; Rosenfeld R
    Nat Commun; 2020 Aug; 11(1):4303. PubMed ID: 32855401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.
    Mamedov T; Yuksel D; Ilgın M; Gurbuzaslan I; Gulec B; Yetiskin H; Uygut MA; Islam Pavel ST; Ozdarendeli A; Mammadova G; Say D; Hasanova G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.
    Hattori T; Koide A; Noval MG; Panchenko T; Romero LA; Teng KW; Tada T; Landau NR; Stapleford KA; Koide S
    J Mol Biol; 2021 Feb; 433(3):166748. PubMed ID: 33310017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
    Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
    Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
    Kim GN; Choi JA; Wu K; Saeedian N; Yang E; Park H; Woo SJ; Lim G; Kim SG; Eo SK; Jeong HW; Kim T; Chang JH; Seo SH; Kim NH; Choi E; Choo S; Lee S; Winterborn A; Li Y; Parham K; Donovan JM; Fenton B; Dikeakos JD; Dekaban GA; Haeryfar SMM; Troyer RM; Arts EJ; Barr SD; Song M; Kang CY
    PLoS Pathog; 2021 Dec; 17(12):e1010092. PubMed ID: 34914812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
    Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.
    Kim YJ; Lee MH; Lee SR; Chung HY; Kim K; Lee TG; Kim DY
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
    Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z
    Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
    Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
    PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.